edurant 25 mg comprimate filmate
janssen-cilag international nv - rilpivirinum - comprimate filmate - 25 mg
aluvia comprimate filmate 200 mg + 50 mg
abbvie biopharmaceuticals gmbh - lopinavirum + ritonavirum - comprimate filmate - 200 mg + 50 mg
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.
simvahexal 40 mg
hexal ag - simvastatinum - compr. film. - 40mg - hipocolesterolemiante si hipotrigliceridemiante inhibitori ai hmg coa reductazei
lopinavir/ritonavir terapia 200mg/50 mg
ranbaxy ireland limited - irlanda - lopinavirum+ritonavirum - compr. film. - 200mg/50mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii
lopinavir/ritonavir sandoz 200 mg/50 mg
salutas pharma gmbh - germania - lopinavirum+ritonavirum - compr. film. - 200mg/50 mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii
lopinavir/ritonavir accord 200 mg/50 mg
accord healthcare limited - marea britanie - lopinavirum+ritonavirum - compr. film. - 200mg/50mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii
euvascor 10 mg/10 mg
les laboratoires servier industrie - franta - combinatii (atorvastatinum+perindoprilum) - caps. - 10mg/10mg - hipolipemiante, combinatii inhibitori de hmg coa reductaza, alte combinatii
euvascor 10 mg/5 mg
les laboratoires servier industrie - franta - combinatii (atorvastatinum+perindoprilum) - caps. - 10mg/5mg - hipolipemiante, combinatii inhibitori de hmg coa reductaza, alte combinatii
euvascor 20 mg/10 mg
les laboratoires servier industrie - franta - combinatii (atorvastatinum+perindoprilum) - caps. - 20mg/10mg - hipolipemiante, combinatii inhibitori de hmg coa reductaza, alte combinatii